Eli Lilly's Retatrutide Shows Strong Weight-Loss Results as Next-Gen Therapy
Eli Lilly has reported phase 3 clinical trial results for retatrutide, a next-generation weight-loss drug that mimics three gut hormones (GLP-1, GIP, and glucagon). Patients on the highest dose lost an average of 28.3% body weight over 80 weeks compared to just 2.2% in the placebo group. This outperforms Zepbound's current efficacy and positions retatrutide as a potential blockbuster for Eli Lilly.
Tickers: $LLY
Topics: Eli Lilly GLP-1/GIP agonists retatrutide weight management Zepbound